Your Cheap Ozempic Just Disappeared. Here Is What Actually Replaced It.
What the 2026 compounding shutdown and the new Medicare GLP-1 Bridge actually mean for your prescription and your wallet
Table of Contents
1. The notification that started all of this
2. What actually happened to compounded GLP-1 medications
3. Why affordability alone was never going to keep the door open
4. Path one: manufacturer direct pricing
5. Path two: Medicare will cover GLP-1s for the first time ever
6. Which path actually applies to you
7. The one requirement every path shares
8. What not to do while you sort this out
9. Getting the prescription and documentation you need this week
10. Frequently asked questions
1. The Notification That Started All of This
You get an email from the pharmacy, or a notification inside the app you have used every month for the last year. The wording is calm and bureaucratic. Your compounded semaglutide prescription will not be available for renewal after a specific date. Underneath the calm wording is a much less calm question.
You have lost forty pounds. Fifty. Eighty. You finally found the thing that worked after years of things that did not. And now you are being told, with very little warning, that the version you could afford is going away.
This happened to an enormous number of people across 2025 and into 2026, and parts of it are still happening. It is not a personal failure, and it is not a scam you fell for. It is the predictable result of a federal rule finally catching up to a temporary exception that was never built to last forever.
The Short Version
The compounded version of semaglutide and tirzepatide that millions of people relied on for an affordable prescription is no longer broadly legal to produce. Two real, lower-cost replacement paths opened at roughly the same time: manufacturer direct-pay pricing, and for the first time in Medicare's history, a federal program that will cover GLP-1 medications prescribed specifically for weight loss. Both paths still require something you may not have right now: a current, documented prescription from a licensed provider.
2. What Actually Happened to Compounded GLP-1 Medications
The shift has two dates that matter. The FDA declared the tirzepatide injection shortage resolved on December 19, 2024. Semaglutide followed in February 2025. Both medications had been added to the federal shortage list years earlier, in 2022, after demand outpaced what manufacturers could produce.
While a drug sits on that shortage list, federal law allows compounding pharmacies to prepare large batches of a chemically identical version to fill the gap, without needing to replicate the brand manufacturer's full approval process. That exception is what made compounded semaglutide and tirzepatide so widely available, and so much cheaper than the brand-name product, for the better part of three years.
Once a shortage is declared resolved, that legal basis disappears with it. According to Pharmacy Times, the FDA followed the shortage resolutions with an escalating enforcement campaign through 2025 and into 2026, issuing more than fifty warning letters to compounding pharmacies and telehealth companies in what trade press has described as the largest single enforcement action in GLP-1 history. Several major telehealth platforms that had built parts of their business around compounded semaglutide exited that line entirely rather than risk enforcement.
A Safety Detail Worth Knowing
The FDA's decision was not purely about supply. Adverse event reports tied to compounded GLP-1 products, including dosing errors from multidose vials that required hospitalization in some cases, were part of the agency's stated rationale for tightening enforcement once the shortage justification was gone.
3. Why Affordability Alone Was Never Going to Keep the Door Open
This is the part that feels the most unfair, and it is worth understanding exactly, because it explains why appealing to a compounding pharmacy or a previous telehealth provider will not bring the old price back.
Compounding law was written to solve a supply problem, not a price problem. The legal standard for continuing to compound a drug after its shortage ends is a documented, individual clinical need that the FDA-approved version cannot meet, such as a verified allergy to an inactive ingredient. The FDA has been explicit that the inability to afford the brand-name product does not meet that standard, regardless of how real the financial barrier is for the patient.
None of that changes the practical reality. A medication that was working stopped being affordable through the channel that made it affordable. The rest of this article is about the two paths that opened to fill that gap, and what each one actually requires from you.
4. Path One: Manufacturer Direct Pricing
Both manufacturers responded to the affordability gap by building their own direct-to-patient pharmacy programs, selling at cash prices well below the retail list price.
NovoCare Pharmacy (Novo Nordisk) sells Wegovy directly to self-pay patients. Oral Wegovy generally runs $149 to $299 a month depending on dose, and injectable Wegovy runs roughly $349 to $499 a month, compared with a retail list price north of $1,300.
LillyDirect (Eli Lilly) sells Zepbound single-dose vials directly to self-pay patients, generally running $299 to $449 a month depending on dose, compared with a retail list price above $1,000.
Neither program requires insurance. Both require something else: a current prescription specific to that exact branded product, written by a licensed provider, because these remain prescription medications regardless of how you pay for them. Self-pay purchases through these programs also do not count toward an insurance deductible or out-of-pocket maximum, which matters if you do have a plan you are otherwise using.
5. Path Two: Medicare Will Cover GLP-1s for the First Time Ever
The bigger structural change applies to people on Medicare. Under longstanding federal law, Medicare Part D has been statutorily prohibited from covering a drug prescribed solely for weight loss since the program's creation in 2006. That changes on July 1, 2026, when the Centers for Medicare and Medicaid Services launches a temporary program called the Medicare GLP-1 Bridge.
Under the Bridge, eligible Part D enrollees pay a flat $50 monthly copay for an eligible GLP-1 medication prescribed specifically for weight reduction, and that copay does not count toward the standard Part D out-of-pocket cap. According to KFF, the program covers all formulations of Wegovy, the KwikPen formulation of Zepbound specifically (not the single-dose vials), and a newly approved medication called Foundayo. The program runs from July 1, 2026 through December 31, 2027, ahead of a longer multi-year demonstration that may follow.
Eligibility is based on body weight and health status. According to NPR, a body mass index of 35 or higher qualifies automatically, and a body mass index of 27 or higher qualifies if it comes with a condition such as heart disease or prediabetes. You must be enrolled in a Medicare Part D plan, and your provider needs to submit prior authorization with clinical documentation showing you meet the criteria before coverage can begin.
Why This Matters Beyond Medicare
Even if you are not on Medicare, the Bridge is a useful signal. It represents the first crack in a sixty-year-old statutory wall, and the political and clinical pressure behind it is part of why manufacturer direct pricing has also been moving in a more affordable direction at the same time.
6. Which Path Actually Applies to You
You are on Medicare Part D.
The Bridge is very likely your most affordable path starting July 1, but the prior authorization paperwork needs to be in motion before that date, not after, since processing takes time.
You are under 65 and your insurance does not cover weight-loss GLP-1s.
Manufacturer direct pricing through NovoCare or LillyDirect is currently the most accessible self-pay route, and it is available immediately.
You are currently on compounded medication with no documented clinical exception.
You need a transition plan in place before your existing supply runs out, built around whichever of the two paths above fits your situation, not after the supply is already gone.
7. The One Requirement Every Path Shares
Manufacturer direct pricing requires a current, product-specific prescription. The Medicare GLP-1 Bridge requires prior authorization built on clinical documentation. Continuing under a narrow compounding exception requires a provider to document a specific clinical need in your chart.
Every legitimate path forward starts in the same place: an actual clinical evaluation by a licensed provider who can document your history, your current status, and which option fits. This is not a workaround to get back to where you were. It is the literal requirement, regardless of which door you walk through.
"Most of the patients coming to me about this in the last few months are not asking how GLP-1 medications work. They already know. What they need is someone to walk through which of the new pathways actually applies to their situation, and to get the paperwork moving before their old supply runs out, not after." -- Casey Hicks, FNP-BC, Founder, Practical Telehealth
8. What Not to Do While You Sort This Out
Do not stop the medication abruptly without medical guidance.
Discontinuing a GLP-1 suddenly is associated with a return of appetite and a meaningful risk of regaining lost weight, since the hormonal mechanism the medication was supporting stops working the moment you stop taking it. For patients also managing blood sugar, stopping can affect glucose control as well.
Do not source medication from unverified online sellers outside a licensed pharmacy channel.
Quality and dosing issues with unregulated compounded or gray-market products have been directly tied to the adverse event reports that helped drive FDA enforcement in the first place.
Do not stretch or split a fixed supply on your own.
Rationing a dwindling supply without medical guidance can produce inconsistent dosing, which can look like a plateau or a side effect flare when it is really an access problem in disguise.
9. Getting the Prescription and Documentation You Need This Week
A virtual visit with a licensed provider at Practical Telehealth can evaluate your history and current treatment status, write or transfer a prescription to use with a manufacturer direct-pay program, or prepare the clinical documentation a Medicare Part D plan needs for a GLP-1 Bridge prior authorization.
The flat fee is $20. No insurance is required for the visit itself, and the appointment is available across approximately two dozen US states, including evenings and outside traditional clinic hours.
Baseline labs are often useful before adjusting or restarting GLP-1 therapy, and these can be ordered through the same visit using online lab orders. If you are navigating this as a Medicare beneficiary specifically, the telehealth Medicare service page covers what else is involved in using Medicare benefits through a virtual visit.
Take the First Step
Book a virtual weight loss consultation at Practical Telehealth to find out which path applies to you and get the documentation moving before your current supply runs out. Flat fee: $20. No insurance required.
Also available: online lab orders | telehealth Medicare | online primary care
10. Frequently Asked Questions
Q: Is compounded semaglutide or tirzepatide still available in 2026?
For most patients, no. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. Once a shortage is officially resolved, federal compounding law generally restricts pharmacies from continuing to prepare large-scale compounded versions for human use. A narrow exception remains for a documented individual clinical need, such as a verified allergy to an inactive ingredient, that a provider determines the approved version cannot meet. Affordability alone does not meet that legal standard.
Q: Why did the FDA stop allowing compounded GLP-1 medications?
Compounding pharmacies are legally permitted to recreate a patented, FDA-approved drug only while that drug sits in a verified national shortage. Once manufacturers confirmed they could meet national demand, the shortage designation ended, and the legal basis for mass compounding ended with it. The FDA also cited safety concerns, including adverse event reports tied to dosing errors from compounded multidose vials, as part of its rationale.
Q: How much does Wegovy or Zepbound cost without insurance now?
Through manufacturer direct-pay programs, oral Wegovy generally runs $149 to $299 a month and injectable Wegovy runs roughly $349 to $499 a month through NovoCare, depending on dose. Zepbound vials through LillyDirect generally run $299 to $449 a month. These programs do not require insurance but do require a current prescription, and pricing can change, so confirming current figures directly with the manufacturer program before assuming a specific number is worthwhile.
Q: Do I qualify for the new Medicare GLP-1 Bridge program?
You generally qualify if you are enrolled in a Medicare Part D plan and either have a body mass index of 35 or higher, or a body mass index of 27 or higher along with a qualifying weight-related condition such as hypertension, prediabetes, or heart disease. The program also requires prior authorization and clinical documentation confirming you meet the criteria. Coverage begins July 1, 2026 and is scheduled to run through December 31, 2027.
Q: What happens if I just stop my GLP-1 medication?
Stopping a GLP-1 medication abruptly without medical guidance is associated with a return of appetite and a meaningful risk of regaining lost weight, since the hormonal mechanism the medication was supporting stops the moment you stop taking it. For patients also using these medications to manage blood sugar, stopping can affect glucose control as well. A licensed provider can help plan a transition rather than an abrupt stop.
Q: Can a telehealth provider prescribe Wegovy or Zepbound?
Yes. A licensed provider conducting a telehealth visit can evaluate clinical history, review relevant labs, and prescribe these medications where clinically appropriate, including writing or transferring a prescription for use with a manufacturer direct-pay program or preparing documentation for a Medicare GLP-1 Bridge prior authorization. Practical Telehealth operates across approximately two dozen US states.
Q: What is the difference between NovoCare and LillyDirect?
NovoCare is Novo Nordisk's direct-to-patient pharmacy program for its own medications, including Wegovy. LillyDirect is Eli Lilly's equivalent program for its medications, including Zepbound. The two programs are specific to each manufacturer's own drugs and are not interchangeable, since Wegovy and Zepbound are different medications from different companies.
Q: Is tirzepatide, the active ingredient in Mounjaro and Zepbound, still in a shortage?
No. The FDA declared the tirzepatide shortage resolved in December 2024, and that determination was upheld in federal court in 2025. As with semaglutide, compounded tirzepatide is now legally restricted outside of narrow, documented clinical-need exceptions.
